Two doses of COVID-19 vaccinations will not suffice to neutralize antibodies against the Omicron variant of the Coronavirus, found British scientists. They further found that those who have been previously infected or vaccinated may face increased infections.

Researchers from the University of Oxford have published results from a study that is yet to be peer-reviewed, wherein they analyzed blood samples from participants who were given doses from AstraZeneca-Oxford or Pfizer-BioNTech in a large study looking into mixing of vaccines.

The results come a day after British Prime Minister Boris Johnson warned that two vaccinations doses against COVID-19 will not be sufficient to not get infected from the Omicron variant.

According to the results of the Oxford study, that there was no evidence, yet, to conclude that lower level of infection-fighting antibodies against Omicron could lead to higher risk of severe disease, hospitalisation or death in those who have got two doses of approved vaccines.

“These data are important but are only one part of the picture. They only look at neutralizing antibodies after the second dose, but do not tell us about cellular immunity, and this will also be tested,” said Matthew Snape, Oxford professor and co-author of the paper.

Categories: Creativity, Economy & Finance, Entrepreneurship, HR & Organization, Strategy, Sustainability

Tags: antibodies, AstraZeneca, Boris Johnson, British, cellular immunity, coronavirus, COVID-19, COVID19, death, hospitalization, infections, Matthew Snape, mixing, neutralize, Omicron variant, Pfizer BioNTech, previously infected, previously vaccinated, Prime Minister, severe disease, two doses, two vaccinations doses, vaccinations, vaccines